|
End-of-day quote
Nasdaq
17/11/2026
|
5-day change | 1st Jan Change | ||
| 1.720 USD | -8.99% |
|
+2.99% | -80.95% |
| 11-16 | EnGene Therapeutics Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 03:20 PM | |
| 11-13 | Leerink Partners Upgrades enGene to Outperform From Market Perform, $5 Price Target | MT |
Company Valuation: enGene Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: October | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | 451.1 | 369.1 | 115.3 | - | - |
| Change | - | - | -18.18% | -68.77% | - | - |
| Enterprise Value (EV) 1 | - | 236 | 190.7 | -69.25 | 40.8 | -25.35 |
| Change | - | - | -19.19% | -136.32% | 158.92% | -162.13% |
| P/E | -0.14x | -6.06x | -3.15x | -0.93x | -1.08x | -1.64x |
| PBR | - | 1.65x | 2.2x | 0.63x | 1.56x | 1.11x |
| PEG | - | 0.1x | -0.1x | 0x | 0.1x | 0x |
| Capitalization / Revenue | - | - | - | - | 24.6x | 2.94x |
| EV / Revenue | - | - | - | - | 8.72x | -0.65x |
| EV / EBITDA | - | -3.81x | -1.55x | 0.57x | -0.34x | 0.2x |
| EV / EBIT | - | -3.79x | -1.55x | 0.54x | -0.34x | 0.25x |
| EV / FCF | - | - | -1.89x | 0.5x | -0.26x | 0.18x |
| FCF Yield | - | - | -52.8% | 200% | -382% | 555% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -151.2 | -1.46 | -2.29 | -1.84 | -1.597 | -1.051 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 4.678 | 39.19 |
| EBITDA 1 | - | -61.97 | -122.7 | -121.4 | -121.3 | -125.7 |
| EBIT 1 | - | -62.3 | -123.2 | -128 | -118.6 | -100.7 |
| Net income 1 | -99.92 | -55.14 | -117.3 | -125.2 | -118.2 | -102.6 |
| Net Debt 1 | - | -215.2 | -178.4 | -184.5 | -74.46 | -140.6 |
| Reference price 2 | 21.695 | 8.850 | 7.210 | 1.720 | 1.720 | 1.720 |
| Nbr of stocks (in thousands) | - | 50,974 | 51,192 | 67,016 | - | - |
| Announcement Date | 29/01/24 | 19/12/24 | 22/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.93x | - | 0.57x | -.--% | 115M | ||
| 17.32x | 6.64x | 12.72x | 1.72% | 66.37B | ||
| 31.83x | 8.5x | 28.08x | 0.07% | 58.86B | ||
| 38.41x | 6.84x | 20.46x | 0.85% | 55.22B | ||
| 44.35x | 6.2x | 29.52x | -.--% | 47.21B | ||
| 33.62x | 3.22x | 13.9x | -.--% | 42.45B | ||
| 35.98x | 8.9x | 23.21x | 0.36% | 36.44B | ||
| -19.28x | 55.7x | -21.11x | -.--% | 35.19B | ||
| 41.59x | 8.02x | 26.91x | -.--% | 32.66B | ||
| -74.36x | 14.09x | -75.73x | -.--% | 26.73B | ||
| Average | 14.85x | 13.12x | 5.85x | 0.3% | 40B | |
| Weighted average by Cap. | 21.60x | 11.64x | 11.38x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ENGN Stock
- Valuation enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
















